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INTRODUCTION: The HIV and TB co-epidemic remains a big obstacle in reducing PLHIV 
mortality and morbidity in Namibia. The solution to that has been the implementation of 
isoniazid preventative therapy (IPT) alongside ART for PLHIV to prevent the development of 
active tuberculosis. As newer shorter regimens of IPT (3HP) are released it is important to 
Namibia’s Ministry of Health to evaluate the efficacy of these newer IPT regimens prior to their 
implementation.  
OBJECTIVES: The objective of this review is to compare the benefit of 3HP to that of 6-month or 
continuous (36-month) daily IPT for PLHIV to make future TB prophylaxis recommendations for 
MOH of Namibia. The review will take into consideration outcomes such as TB incidence, 
mortality, completion rate, and adverse events. 
METHODS: The qualifying studies were randomized controlled trials which consisted of 
participants being provided with 3HP and daily IPT (6 month or continuous). Only studies that 
primarily enrolled PLHIV were included in this review. Out of all the results of these studies the 
interest is in the development of active tuberculosis, mortality, adverse events, and treatment 
completion rate. 
RESULTS: The analysis of the two studies that qualified for this review informs us that 3HP has 
similar efficacy in preventing active tuberculosis to that of IPT. The Sterling study reported that 
discontinuation due to hepatotoxicity was significantly higher in the 9-month IPT arm (4%) than 
in the 3HP (1%) arm. Hepatoxicity was reported in 1.4% (3/207) of the participants in the 3HP 
group compared to 6.5% (12/193) of the 9-month IPT groups. Both studies reported a higher 
completion and adherence rate for 3HP than for 6-month or 9-month IPT. The highest 
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adherence was reported for the 3HP in the Martinson study at 95.7% whereas 6-month IPT had 
an adherence rate for only 83.8%.  
CONCLUSION: Largely, this review suggests that further research be done to evaluate the 
complexity of 3HP in different settings with different populations. However, based on these 
preliminary findings it is preferable for Namibia to adopt 3HP once it is cost-effective to raise 



















I. BACKGROUND .............................................................................................................................6 
WHAT IS TUBERCULOSIS? ...................................................................................................................6 
WHY ARE TB AND HIV SO INTERLINKED?..............................................................................................7 
WHAT ARE THE CURRENT TREATMENT MEASURES FOR PLHIV? ............................................................7 
WHAT IS ISONIAZID PREVENTION THERAPY? .......................................................................................8 
OBJECTIVE: ...................................................................................................................................... 11 
II. METHODS ................................................................................................................................. 12 
ETHICS STATEMENT: ......................................................................................................................... 12 
SEARCH STRATEGY: .......................................................................................................................... 12 
ELIGIBILITY CRITERIA: ....................................................................................................................... 12 
III. RESULTS................................................................................................................................... 13 
DESCRIPTION OF INCLUDED STUDIES: ............................................................................................... 13 
TB INCIDENCE AND MORTALITY: ....................................................................................................... 15 
ADVERSE EVENTS: ............................................................................................................................ 16 
COMPLETION RATE: ......................................................................................................................... 17 
IV. DISCUSSION ............................................................................................................................. 18 
CURRENT IMPLEMENTATION OBSTACLES: ......................................................................................... 19 
EFFICACY: ........................................................................................................................................ 21 
COST-EFFECTIVENESS: ...................................................................................................................... 21 
LIMITATIONS: .................................................................................................................................. 21 
V. CONCLUSION ............................................................................................................................ 22 








LIST OF TABLES 
TABLE 1- LIST OF IPT + ART VS ART ALONE STUDIES ........................................................................... 9 
TABLE 2- LIST OF CONTINUOUS IPT VS 6-MONTH IPT STUDIES ................................................................ 9 
TABLE 3- LIST OF INCLUDED STUDIES IN THIS REVIEW .......................................................................... 13 
TABLE 4- TB INCIDENCE AND MORTALITY MARTINSON ET AL. ............................................................... 15 































WHAT IS TUBERCULOSIS? 
Tuberculosis (TB) is one of the top ten leading causes of death worldwide due to a single 
infectious agent. In 2018 alone, it was responsible for killing 1.5 million people with 10 million 
people experiencing the illnessi. In addition to affecting so many around the world it can be 
found in all countries despite being a preventable disease. In an ideal world timely diagnosis 
and treatment would be available to all thus drastically reducing transmission and severity of 
the illness. However, due to the lengthy treatment and lack of feasible diagnostic measures that 
is not necessarily the case. The eradication of TB is complicated by the route of transmission of 
the bacteria as well as the latent stage of the disease. A latently infected individual will not 
develop any of the symptoms associated with the illness, and of the latently infected individuals 
5-10% will go on to develop the disease. Currently, almost 1.7 billion people around the world 
are infected with TB and thus are at risk for active tuberculosisi. People with the disease 
typically exhibit unexplained weight loss, lack of appetite, night sweats, fever and chills. Those 
with pulmonary tuberculosis will additionally develop chest pain, persistent cough and 
hemoptysis. Those exhibiting symptoms are considered infectious and capable of spreading the 
TB bacteria to others. Thus, it is imperative to minimize the development of disease especially 
for the immunosuppressed. 
 
In 2018, the TB burden in Namibia was 0.524% (524/100,000) with the mortality at 
0.064% (64/100,000)ii. However, this number does not capture the whole story of TB associated 
mortality. Out of the 13,000 individuals affected with TB, 4500 were HIV-positiveii. The fact that 
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36% of TB patients have an HIV-positive status is alarming. Globally, Namibia remains one of 
the most HIV prevalent countries. In 2018, the prevalence of HIV in the country was at 11.8% 
with 2,400 AIDS related deathsii. This highlights that there is a large population of people living 
with HIV (PLHIV) that are vulnerable to developing tuberculosis. The co-epidemic of HIV and 
tuberculosis (TB) remains a major public health crisis.  
 
WHY ARE TB AND HIV SO INTERLINKED? 
The human immunodeficiency virus (HIV) is an infection in which the CD4 T-lymphocytes 
are targeted. By preferentially targeting the CD4 lymphocytes the immune system is left 
weakened. For someone living with HIV the risk of developing TB is 20-37 times greater than for 
those that are HIV negativeiii. For an HIV negative individual, the risk progressing from latent TB 
to active TB is 10%, but for PLHIV this risk is 30%iv. Thus, HIV remains the strongest risk factor 
for TB disease progression and severity. An HIV infection increases one’s risk of latent TB 
reactivation. Individuals suffering from a TB and HIV co-infection experience faster disease 
progression rates and have a higher risk of mortality. There is an inverse relationship between 
CD4 lymphocyte count and risk of active TB, as CD4 cell count declines the risk for active TB 
increases. Numerically, this relationship is seen as a 15-20% increased risk of active TB per year 
for PLHIV with CD4 cell counts of less than 200 cells/lv. In areas of high prevalence of HIV there 
remains a need to implement TB control measures in order to keep PLHIV protected as well as 
stop the TB epidemic.   
 
WHAT ARE THE CURRENT TREATMENT MEASURES FOR PLHIV?  
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In order to assess the need for further prophylaxis, it is important to first analyze what 
measures are currently implemented for PLHIV. Through PEPFAR there has been a global scale-
up of HIV care all over Africa. This scale-up includes treatment services, in particular, 
antiretroviral therapy (ART). PEPFAR is currently implemented in Namibia for three strategic 
areas; prevention of HIV transmission, care and treatment of PLHIV, and strengthening the 
public health system to effectively and sustainably respond to the epidemicvi. Through PEPFAR, 
Namibia is trying to achieve the UNAIDS 90-90-90 targetsvii. These targets will ensure that 90% 
of all PLHIV know their status, 90% of those who know their status are on ART and lastly 90% of 
those on treatment are able to achieve viral suppressionviii. The second 90 is important because 
it is concerning treatment for PLHIV with ART. Currently, all PLHIV in Namibia are eligible for 
ART upon being diagnosed. Those with a positive HIV test are referred to an ART clinic to be 
further assessed and to begin the ART regimen. All this effort has given significant results 
because as of 2018, 76.5% of PLHIV are on ART and 87% of those on ART have viral suppression. 
This is proof that Namibia is on its way to achieve the UNAIDS 90-90-90 targets. ART is also 
known to be associated with rapid recovery of mycobacteria-specific immune responses. This 
leads to decreased mycobacterial growth and at the clinical level has shown to be a powerful TB 
preventative effect. Since the advent of ART, analysis has shown there to be 65% reduction in 
TB incidence in PLHIV.  
 
WHAT IS ISONIAZID PREVENTION THERAPY?  
 However, due to the increased risk of tuberculosis for PLHIV there is a need for more 
prophylaxis beyond just antiretroviral therapy. Moreover, TB rates still remain relatively high 
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even after increasing ART uptake among PLHIV; thus, highlighting the need for continued focus 
on TB control measures. Currently, ART is accompanied by the implementation of isoniazid 
preventative therapy (IPT). IPT has been widely used as prevention for TB. It eliminates the 
bacterium from the body by treating latent tuberculosis and preventing new infections from 
occurring during treatmentix. Alongside ART, IPT provides an additional blanket of protection 
for PLHIV to prevent tuberculosis. Several studies show that IPT alongside ART provides 
additional benefits in lowering the incidence of TB than just the implementation of ART alonex. 
(Table 1)  
 
Table 1- List of IPT + ART vs ART alone studies 
Study  Type  Key findings 
Edessa 2015iii Retrospective cohort study at 
TASH and ZMH 6-month IPT + 
ART and ART alone 
For ART alone TB incidence: 
10/100 PY, For IPT + ART TB 
incidence: 4.5/100 PY 
Badje, TEMPRANO ANRS 
12136, 2017xi 
RCT for 6-month IPT + ART in 
Cote d’Ivore 
35% reduction in HIV related 
deaths after initiation of IPT 
Golub, THRio, 2007xii 
 
Prospective cohort; Brazil For ART alone TB incidence: 
1.9/100 PY, For IPT + ART TB 
incidence: 0.8/100 PY  
Golub, 2009xiii  Prospective cohort; South 
Africa  
For ART alone TB incidence: 
4.6/100 PY, For IPT + ART TB 
incidence: 1.1/100 PY 
Yirdaw, 2014xiv Retrospective cohort; 
Ethiopia 
For ART alone TB incidence: 
0.74/100 PY, For IPT + ART TB 
incidence: 0.36/100 PY 
Rangka, 2014xv RCT; South Africa For ART alone TB incidence: 
3.6/100 PY, For IPT + ART TB 
incidence: 2.3/100 PY 
 
Table 2- List of continuous IPT vs 6-month IPT studies 
Study  Type  Key findings 
Samandari, 2011xvi RCT; Botswana 6-month IPT: 34 cases/989 
participants (3.4%) 
Continuous IPT: 20 
cases/1006 (2.0%) 
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Kunkel, 2016xvii Transmission Dynamic 
Model; Botswana 
Benefits of continuous IPT 
outweigh the risk of long 
duration of IPT in reduction 
of TB incidence and 
mortality. 
Swaminathan, 2012xviii RCT; India Both regimens were similarly 
effective, 36 months showed 
a lower trend of TB 
incidence. 
6 months: 2.4/100py  
Continuous IPT: 1.6/100py 
Hsieh, 2018xix Transmission Dynamic 
Model, Malawi 
Compared to the 6-month 
IPT program, the continuous 
IPT can avert at least 6902 
more TB cases and prevent 
2256 deaths. 
 
Through the analysis of these studies it is clear that when ART is combined with IPT 
there is greater reduction of mortality for PLHIV. This is due to the fact that IPT lowers the risk 
of active tuberculosis in high endemic settings for those that are extremely vulnerable (PLHIV). 
Thus, WHO recommends that IPT be given to all PLHIV in combination with ART starting at the 
time of diagnosisix.  
The current recommendation is that IPT be given continuously for at least 6 months. 
Additionally, in high TB endemic areas it is recommended that IPT be given for 36 continuous 
months. For example, in countries like Botswana, where incidence of TB is at 350 per 100,000, 6 
months of IPT can be insufficient. In a randomized, double-blind, placebo-controlled trial 
conducted in Botswana it was discovered that 36 months of continuous IPT given to PLHIV 
reduced TB incidence by 43% when compared to 6 months of IPTxvi. It should be noted that this 
benefit was seen in those with a tuberculin positive test. (39) The Swaminathan randomized 
clinical trial in India had similar findings in which 712 PLHIV were randomized to receive either 
6-month IPT or continuous IPT (36 months)xviii. The results showed a decreased TB incidence for 
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continuous IPT when compared to 6-month IPT (6 months: 2.4/100py, continuous IPT: 
1.6/100py).  
In comparison the TEMPRANO study conducted in West Africa, where the incidence of 
TB in 159 per 100,000 people, concluded that 6 months of ART + IPT has durable protective 
effect in reducing mortality in PLHIV when taken along with ARTxi. After the analysis of current 
available studies, it can be concluded that the length of IPT is context-specific and can be 
proportional to the burden of tuberculosis in the countryix. (Table 2) 
While 6-month IPT is part of the current WHO guidelines for TB prophylaxis there is 
another treatment option of 3-month weekly regimen of rifapentine plus isoniazid (3HP) that is 
recommended for high- or upper-middle-income countries with a TB incidence of 
<100/100,000. The shorter duration and simplicity offered by the 3 month-once weekly 
regimen has major appeal for the future of IPT. Since the advent of 3HP in 2011, many studies 
have confirmed 3HP’s effectiveness when compared to alternative IPT regimensi. 
Since 3HP, an even shorter course regimen of daily isoniazid and rifapentine for 28 days 
(1HP) has been formulated. Due to its extremely short regimen it will have even fewer barriers 
towards implementation and completion rate than 3HP. This shorter regimen is not currently 
available to be implemented and this will not be further discussed in this reviewi.  
 
OBJECTIVE: 
The objective of this review is to compare the benefit of 3HP to that of 6-month or 
continuous (36-month) daily IPT for PLHIV to make future TB prophylaxis recommendations for 
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Namibia. The review will take in consideration outcomes such as TB incidence, mortality, 




Ethical approval was not required for this review. 
 
SEARCH STRATEGY: 
The search was conducted on the PubMed electronic database. The strategy was to use the 
terms IPT, rifapentine, 3HP, PLHIV, and RCT. The search was limited to those that were 
randomized controlled trials and the search span included studies that were published between 
1 January 2011 and 1 January 2019. This was done so all studies that were done after the 
introduction of 3HP can be evaluated. The reference lists of included papers were also checked 
and reviewed to get additional studies. No language or geographical limitations were applied.  
 
ELIGIBILITY CRITERIA: 
The qualifying studies were randomized controlled trials which consisted of participants being 
provided with 3HP and daily IPT (6 month or continuous). Only studies that primarily enrolled 
PLHIV were included in this review. Out of all the results of these studies the interest is in the 
development of active tuberculosis, mortality, adverse events, and treatment completion rate. 
For the purposes of this review the 6-month IPT and 9-month IPT regimen were considered 
equivalent. Information taken from each article included study design, comparison groups, 
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number of participants, and the impact of the intervention through risk ratios. There is however 
extensive heterogeneity between the study populations, study methods and settings which 
needs to be taken into consideration when drawing any conclusionsxx. 
 
Table 3- List of included studies in this review 
Study  Country Participants 
Martinson, 2011xxi South Africa 3HP: 328 
6H: 327 
Continuous IPT: 164 
Sterling, 2016xxii USA, Canada, Brazil, Spain, 
Hong Kong, and Peru 
3HP: 206 
9H*: 193 




The studies (Table 3) included in this analysis have been analyzed in prior reviews. Since 
the last systematic review there has not been another study that qualifies for this analysis. 
However, this review will focus on outcomes of interest (TB incidence, mortality, adverse 
events, and completion rate) and then will proceed to discuss the feasibility of implementation 
of 3HP in the Namibia setting.  
 
DESCRIPTION OF INCLUDED STUDIES: 
Martinson et al-  
• The study included randomly assigned South African adults with HIV infection. All 
participants had a positive tuberculin test and were not initiated on ART. The study arms 
were: rifapentine (900 mg) and isoniazid (900 mg) weekly for 12 weeks (3HP), rifampin 
(600 mg) and isoniazid (900 mg) twice weekly for 12 weeks (3HP-2), isoniazid (300 mg) 
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daily for up to 6 years (continuous isoniazid), and isoniazid (300 mg) daily for 6 months 
(6-month IPT control group).  
• Study population was a Soweto community with high prevalence of HIV infection and 
tuberculosis. The eligible participants were at least 18 years of age, were not pregnant 
of breast feeding and did not have active tuberculosis that was ruled out both through a 
comprehensive symptom review and through chest radiography. Patients that had 
previously received tuberculosis preventative therapy were excluded from the study.  
• Treatment for the 3HP & 3HP-2 regimen was directly observed in study clinics while the 
6-month and continuous IPT were self-administered. Patients were assigned in a 
randomly generated algorithm format in 2:2:2:1 block for the 4 treatments groups of 
3HP, 3HP-2, 6-month IPT and continuous IPT, respectively.  
 
Sterling et al-  
• An open-label, randomized noninferiority trial that compared once-weekly rifapentine 
600–900 mg plus isoniazid given under direct observation(3HP) with self-administered 
9-month daily IPT for participants at high risk for tuberculosis.  
• Participants from the United States, Spain, Brazil, Canada and Hong Kong were enrolled 
from June 2001 and December 2010, additionally participants from Peru and Brazil were 
enrolled from February 2008 and December 2010. The participants were followed 
through September 2013. HIV testing was only recommended and not enforced for the 
enrollment for this trial. Patients (≥ 2 years) with an HIV infection and a positive 
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tuberculin test (or had close contact with an active tuberculosis case) were enrolled in 
the study.  
• Treatment was allocated in randomized fashion. For household clusters, the first person 
in the group was randomized to an intervention and the same treatment was given to 
the rest of the cluster. Those with a suspected positive case of tuberculosis, previous 
isoniazid therapy, pregnant or breastfeeding were excluded from the study. Participants 
were followed for 33 months from enrollment and went through a monthly evaluation 
process. After completion of therapy study visits occurred every 3 months up until the 
21st month.  
 
TB INCIDENCE AND MORTALITY: 
Table 4- TB incidence and mortality Martinson et al. 
Incidence  3HP 3HP-2 Continuous IPT 6-month IPT All 
Cases 24 24 8 22 78 
PY follow up 1187.5  1219.7 561.0 1143.9 4112.1 
Incidence rate 
per 100 PY 
2.0 2.0 1.4 1.9 1.9 
 
The incidence rate of tuberculosis incidence and mortality was not significantly different 
between the 3HP and 6-month IPT groups. The incidence rate-ratio for incidence and mortality 
of 3HP was 0.87 when compared to the reference of 6-month IPT (1.0). The p-value was 0.54 
signaling that there was no statistically significant difference between the two regimens. In 
total tuberculosis was diagnosed for 78 patients of which 62 had a confirmed tuberculosis, 11 
Mortality 3HP 3HP-2 Continuous IPT 6-month IPT All 
Deaths 17 16 8 25 66 
PY follow up 1223.6 1269.8 574.2 1180.0 4247.6 
Incidence rate 
per 100 PY 
1.4 1.3 1.4 2.1 1.6 
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had probable tuberculosis and 5 had possible tuberculosis. Out of the all participants, 66 
patients died during the follow-up. No significant differences in the incidences of tuberculosis 
or death was seen between all three shorter regimen treatment groups. The rate of 
tuberculosis and mortality was lower in the continuous isoniazid groups than in the other three 
groups. (Table 4) 
 
Table 5- TB incidence and mortality Sterling et al. 
TB Incidence  3HP 9-month IPT 
Total Participants 206 193 
TB cases 2 6 
Incidence rate per 100 PY 0.39 1.25 
 
There were 2 tuberculosis cases in the 3HP arm in the 517 person-years of follow up and 6 
tuberculosis cases in the 481 person-years of follow up for the 9-month IPT arm. Since this was 
a non-inferiority trial the margin for non-inferiority was defined as the difference in cumulative 
TB rates of 0.75%. Non-inferiority was reached within the modified intention-to-treat analysis 
(upper limit of the 95% CI 0.60). Non-inferiority was not reached in the per-protocol analysis 
(upper limit of the 95% CI 1.47). A previous systematic review conducted a meta-analysis which 
failed to show a significant difference in the risk for active TB between the two treatment 
groups. Additionally, there was no significant difference in mortality between the 3HP and 9-
month IPT for adults with HIV.  
 
ADVERSE EVENTS: 
Martinson et al -  
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The shorter regimens (3HP, 3HP-2, 6-month IPT) all had adverse events likely to occur after the 
completion of the treatment whereas the continuous regimen saw 87.3% of adverse events 
occurring in duration of the medication phase. Serious adverse events included grade 3 or 4 
toxic effects, death and active tuberculosis. For 3HP arm the rate of adverse events was 8.7 per 
100 PY, 3HP-2 had a rate of 10.6 per 100 PY, continuous isoniazid group had a rate of 18.4 per 
100 PY and 15.4 per 100 PY for the 6-month isoniazid group. No deaths were reported from the 
drug regimen itself. This study did report an increase in aspartate or alanine aminotransferase 
levels during treatment phase. The proportion of participants experiencing this increase was 
1.5% in 3HP, 2.4% in 3HP-2, 28% in continuous IPT and 5.5% in 6-month IPT.  
 
Sterling et al -  
Discontinuation due to hepatotoxicity was significantly higher in the 9-month IPT arm (4%) than 
in the 3HP (1%) arm. Hepatoxicity was reported in 1.4% (3/207) of the participants in the 3HP 
group compared to 6.5% (12/193) of the 9-month IPT groups. A significantly lower risk of 
hepatoxicity is present in participants taking 3HP than in those taking 9-month IPT. The risk of 
grade 3 or 4 adverse was also lower in patients given 3HP over 9-month IPT regimen.  
 
COMPLETION RATE: 
Both studies reported a higher completion and adherence rate for 3HP than for 6-month or 9-
month IPT. The highest adherence was reported for the 3HP in the Martinson study at 95.7% 
whereas 6-month IPT had an adherence rate for only 83.8%. In the Sterling study treatment 
completion was significantly higher in the 3HP arm than in the 9-month arm. In the 3HP arm 
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89% (183/206) reported completion whereas only 64% (123/193) reported treatment 
completion in 9-month IPT arm. This was a statistically significant result as the p-value was less 
than 0.001. Since there is heterogeneity between the two studies regarding the length of the 
IPT regimens they are not fully comparable. The point worth noting is that both studies favored 
3HP for adherence and completion no matter what it was being compared toxx.  
IV. DISCUSSION 
 
The objective of this review was to assess the efficacy of 3HP as an alternative 
tuberculosis prophylaxis regimen to 6-month IPT. This is an important public health question 
because for many countries that have high HIV and tuberculosis burden the benefits offered by 
a shorter and simpler regimen can reduce morbidity and mortality associated with an active 
tuberculosis infection.  
Although, IPT has been a World Health Organization (WHO) recommendation for PLHIV 
and children <5 years exposed to persons with TB since 1993, global IPT uptake has remained 
slow.  Of the 34.5 million adults living with HIV, only 4.8 million (14%) were ever reported to 
have been started on IPT since 1993xxiii. Namibia’s 2016 HIV Guidelines recommends that all 
PLHIV in whom TB disease has been excluded should receive 9 months of IPT. Under the U.S. 
President’s Emergency Plan for AIDS Relief, of the 176,126 PLHIV currently receiving ART in 
Namibia, only 41,612 are recorded as having completed a course of IPT between the end of 
2014 and mid 2019. This suggests that 134,514 PLHIV in Namibia remain untreated. Namibia’s 
2020 PEPFAR target for the number of PLHIV that are expected to complete TPT is 82,042. To 
achieve this ambitious goal, programmatically a more feasible approach that delivers treatment 
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widely and successfully will need to be implemented. One avenue is to explore utilizing the 
isoniazid-rifapentine (3HP) regimen. The shorter course of therapy offers the prospect of 
improving acceptance and adherence most notably increasing completion rates of IPT in a 
programmatic setting.  
 
CURRENT IMPLEMENTATION OBSTACLES:  
There are many obstacles to IPT implementation, the foremost being adherence to 
treatment and adverse events.  
Adherence is difficult to achieve for the IPT regimen in place today due to the length 
and rigidness of the therapy. Once a patient starts to feel well it is hard to adhere to a regimen 
that requires months to complete. In countries worldwide IPT completion rates are between 
37% to 95% due to issues with adherence. Namibia faces this issue as well since many of their 
local sites are below 85% for IPT completion rates. Poor adherence essentially negates any 
benefit IPT might provide to the patientxxiv. In order to maximize efficacy of the regimen it is 
important that adherence and completion of the therapy remain a top priority. As discussed in 
the results section of this review both studies reported higher completion and adherence rates 
for 3HP when compared to either the 6 or 9-month IPT with statistical significance. The Sterling 
study is comparable to Namibia because it compared 3HP to 9-month IPT (which is the WHO 
recommendation for Namibia). In the study, the 9-month IPT arm only reported 64% 
completion whereas 3HP was at 89%. This is evidence that if 3HP is implemented in Namibia 
the current completion issues faced by the country can be somewhat alleviated. It is worth 
considering the differences between the setting of the Sterling study and Namibia when 
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drawing any conclusions. However, the future of IPT still looks optimistic if we take into 
consideration the available study data regarding 3HP.  
Another notable obstacle in the success of isoniazid preventative therapy is the onset of 
adverse events. There notable toxicities associated both with isoniazid and ART which make it 
difficult to understand the causative agent when adverse events occur for PLHIV on IPTxxi. The 
worst adverse event is isoniazid associated hepatotoxicity. Isoniazid can cause an elevation in 
liver enzymes, however if it is less than three times the normal amount it is resolvable. This can 
usually be mitigated through cessation of regimen. The risk for hepatoxicity increases with age, 
immunosuppression, hepatitis and consumption of alcohol. Per the WHO recommendations the 
participants must be thoroughly screened and monitored to avoid cases of hepatoxicity. 
However, such monitoring is not always available leaving PLHIV on IPT vulnerable to the onset 
of adverse events. In both of the studies analyzed in this review lower hepatoxicity was 
reported in the 3HP arm than in the 6-month or 9-month IPT arm. Additionally, fewer people 
discontinued the medication due to hepatoxicity in the 3HP arm than in the 6-month or 9-
month IPT arm. While more studies are needed to fully assess the hepatoxicity of isoniazid 
therapy it is clear that taking a potentially strong medication in fewer doses for a shorter 
regimen is preferable to taking it daily for 6-36 months. Thus, to promote both adherence and 
reduce hepatoxicity implementing 3HP in place of 9-month IPT in Namibia is a worthwhile 
endeavor.  
Due to its shorter regimen it can additionally be noted that in countries, including 
Namibia, where implementation of IPT has been slow 3HP may provide a benefit in 




In terms of efficacy it is clear that 3HP has a similar efficacy in preventing active TB when 
compared to daily isoniazid therapy through the analysis of onset of tuberculosis cause and all-
cause mortality. As discussed it is not only more efficacious but also has a higher treatment 
completion rate and fewer adverse events. When discussing efficacy, it only applies when 
comparing 3HP to 6 or 9-month IPT and not continuous IPT. Another systematic review along 
with a modeling study has reported a lower risk of tuberculosis among participants receiving 
continuous IPT in the place of 6-month IPT. Thus, further research is needed when deciding 
between 3HP and continuous IPTxx.  
 
COST-EFFECTIVENESS: 
One of the biggest challenges in implementing 3HP is the price. The cost of rifapentine is 
higher than that of isoniazid. Additionally, since this regimen is not self-administered there is an 
additional cost associate with directly observed therapy (DOT). The need for additional personal 
for DOT is a barrier to implementation due to cost and training required. The more flexibility 
available for any prophylaxis regimen the higher the adherence and lower the discontinuation 
of the medication. The price of rifapentine is $6 per dose in the United States, but the price for 
the countries in need is still far from being cost-effective. Until a decrease in the price is 




There are significant limitations in this analysis. In order to provide accurate 
recommendation for Namibia a 3HP randomized controlled trial needs to be conducted in a 
similar environment with a similar population. Secondly, the last trial was conducted four years 
ago, and thus newer data is required to confirm the findings from the previous studies. 
Additionally, data on children with HIV is limited and thus the conclusions drawn from this 
review is not applicable on that population. Lastly, there are studies available on the added 
benefit of continuous IPT. Thus, in order to attain information on how 3HP performs against 
continuous IPT further studies need to be conducted.  
V. CONCLUSION 
The analysis of the two studies that qualified for this review inform us that 3HP has similar 
efficacy in preventing active tuberculosis to that of IPT. In addition, it is also noted that from the 
data collected in the two studies there are fewer adverse events and higher adherence in the 
participants receiving 3HP compared to the other regimens. The discussed limitations identify a 
gap in research regarding the effectiveness of 3HP to that of continuous IPT. Largely, this review 
suggests that further research be done to evaluate the complexity of 3HP in different settings 
with different populations. However, based on these preliminary findings it is preferable for 
Namibia to adopt 3HP once it is cost-effective to raise their IPT completion rates, increase 
implementation of IPT in all local sites, and prevent adverse outcomes.  
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